Neoleukin Therapeutics Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 7

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 1

Neoleukin Therapeutics General Information

Description

Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefits over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, which is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.

Contact Information

Website
www.neoleukin.com
Formerly Known As
AquaGenyx Pharmaceuticals, Aquinox Pharmaceuticals
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 188 East Blaine
  • Suite 450
  • Seattle, WA 98102
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Acquirer
Neurogene
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 188 East Blaine
  • Suite 450
  • Seattle, WA 98102
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neoleukin Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 18-Dec-2023 Completed Generating Revenue
10. Secondary Transaction - Open Market 31-Jan-2017 Completed Generating Revenue
9. Secondary Transaction - Open Market 31-Jan-2016 Completed Generating Revenue
8. IPO 07-Mar-2014 Completed Generating Revenue
7. Later Stage VC (Series C) 03-Apr-2013 Completed Generating Revenue
6. Later Stage VC 28-Sep-2011 Completed Generating Revenue
5. Later Stage VC 10-Feb-2011 Completed Generating Revenue
4. Later Stage VC (Series B) 18-Jun-2010 Completed Generating Revenue
3. Early Stage VC (Series A) 12-Jun-2007 $14.5M $14.5M Completed Product Development
2. Seed Round Completed Product Development
To view Neoleukin Therapeutics’s complete valuation and funding history, request access »

Neoleukin Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo pro
Drug Discovery
Seattle, WA
7 As of 2023

Zurich, Switzerland
 

Shanghai, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neoleukin Therapeutics Competitors (136)

One of Neoleukin Therapeutics’s 136 competitors is Araris, a Formerly VC-backed company based in Zurich, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Araris Formerly VC-backed Zurich, Switzerland
EpimAb Biotherapeutics Venture Capital-Backed Shanghai, China
Apellis Pharmaceuticals Formerly VC-backed Waltham, MA
Cytovance Biologics Formerly PE-Backed Oklahoma City, OK
Palobiofarma Venture Capital-Backed Barcelona, Spain
You’re viewing 5 of 136 competitors. Get the full list »

Neoleukin Therapeutics Patents

  • 29

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

Neoleukin Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024006961-A1 Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells Inactive 01-Jul-2022
WO-2023052541-A1 Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy Inactive 30-Sep-2021
WO-2023044318-A2 Interleukin-2 receptor βeta (il-2rβ) binding polypeptides Inactive 15-Sep-2021
WO-2023044318-A3 Interleukin-2 receptor βeta (il-2rβ) binding polypeptides Inactive 15-Sep-2021
AU-2021251760-A1 De novo protein decoys of angiotensin-converting enzyme 2 (ace2) Inactive 07-Apr-2020 C07K14/70596
To view Neoleukin Therapeutics’s complete patent history, request access »

Neoleukin Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neoleukin Therapeutics Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Augment Investments Corporation Minority
BC Advantage Funds Venture Capital Minority
Baker Brothers Investments Hedge Fund Minority
Five Corners Capital Venture Capital Minority
Johnson & Johnson JJDC Corporate Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Neoleukin Therapeutics Acquisitions (2)

Neoleukin Therapeutics’s most recent deal was a Reverse Merger with Neurogene. The deal was made on 19-Dec-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Neurogene 19-Dec-2023 Reverse Merger Drug Discovery
Neoleukin Therapeutics (Drug Discovery) 08-Aug-2019 Merger/Acquisition Drug Discovery
To view Neoleukin Therapeutics’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Neoleukin Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Neoleukin Therapeutics’s complete esg history, request access »

Neoleukin Therapeutics FAQs

  • When was Neoleukin Therapeutics founded?

    Neoleukin Therapeutics was founded in 2003.

  • Where is Neoleukin Therapeutics headquartered?

    Neoleukin Therapeutics is headquartered in Seattle, WA.

  • What is the size of Neoleukin Therapeutics?

    Neoleukin Therapeutics has 7 total employees.

  • What industry is Neoleukin Therapeutics in?

    Neoleukin Therapeutics’s primary industry is Drug Discovery.

  • Is Neoleukin Therapeutics a private or public company?

    Neoleukin Therapeutics is a Private company.

  • What is Neoleukin Therapeutics’s current revenue?

    The current revenue for Neoleukin Therapeutics is .

  • How much funding has Neoleukin Therapeutics raised over time?

    Neoleukin Therapeutics has raised $109M.

  • Who are Neoleukin Therapeutics’s investors?

    Augment Investments, BC Advantage Funds, Baker Brothers Investments, Five Corners Capital, and Johnson & Johnson JJDC are 5 of 9 investors who have invested in Neoleukin Therapeutics.

  • Who are Neoleukin Therapeutics’s competitors?

    Araris, EpimAb Biotherapeutics, Apellis Pharmaceuticals, Cytovance Biologics, and Palobiofarma are some of the 136 competitors of Neoleukin Therapeutics.

  • When was Neoleukin Therapeutics acquired?

    Neoleukin Therapeutics was acquired on 18-Dec-2023.

  • Who acquired Neoleukin Therapeutics?

    Neoleukin Therapeutics was acquired by Neurogene.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process